Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$0.92 USD

0.92
5,160,078

+0.01 (1.13%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.93 +0.01 (0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

by Zacks Equity Research

There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

    Celgene Provides 2017 Preliminary Results & 2018 View

    by Zacks Equity Research

    Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.

      4 Biotech Stocks That More Than Doubled This Year

      by Zacks Equity Research

      We take a look at a few biotech stocks whose price has increased more than 100% in 2017.

        CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More

        by Zacks Equity Research

        The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.

          Company News For Dec 12, 2017

          by Zacks Equity Research

          Companies in the news are: KMG,ARGX,BPMC,BLUE

            Bluebird's Shares Jump on Strong Data for CAR-T Therapy

            by Zacks Equity Research

            bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.

              Novartis Reports Updated Results from Kymriah's JULIET Study

              by Zacks Equity Research

              Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.

                Ryan McQueeney headshot

                Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today

                by Ryan McQueeney

                Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.

                  Gilead Sciences to Acquire Cell Design Labs for $567 Million

                  by Zacks Equity Research

                  Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.

                    Celgene CAR-T Therapy Gets Breakthrough Therapy Designation

                    by Zacks Equity Research

                    FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.

                      Why Earnings Season Could Be Great for bluebird bio (BLUE)

                      by Zacks Equity Research

                      bluebird bio (BLUE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                        Sweta Killa headshot

                        5 Top Performing Stocks of the Top ETF of August

                        by Sweta Killa

                        Inside the top performing ETF of August and its top stocks.

                          bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session

                          by Zacks Equity Research

                          bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

                            Ryan McQueeney headshot

                            Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap

                            by Ryan McQueeney

                            The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.

                              Kevin Cook headshot

                              Indecision Won't Kill You, But It Will Take Your Money

                              by Kevin Cook

                              The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.

                                Ryan McQueeney headshot

                                Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition

                                by Ryan McQueeney

                                Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).

                                  Novartis CAR-T Therapy Drug Recommended by FDA Panel

                                  by Zacks Equity Research

                                  Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).

                                    bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session

                                    by Zacks Equity Research

                                    bluebird bio saw its shares rise almost 9% on the day on the back of the company's recently released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma..

                                      bluebird Stock Up on Positive Interim Multiple Myeloma Data

                                      by Zacks Equity Research

                                      bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.

                                        Madeleine Johnson headshot

                                        Here's Why Bluebird Bio (BLUE) is Rallying Today

                                        by Madeleine Johnson

                                        On Thursday, shares of Bluebird Bio Inc. (BLUE) are rallying, up over 17% in midday trading after positive results came in for its experimental anti-BCMA CAR (chimeric antigen receptor) T-cell product candidate bb2121.

                                          David Bartosiak headshot

                                          Bear of the Day: Conn's (CONN)

                                          by David Bartosiak

                                          With shoppers moving from bricks to clicks retailers are really struggling

                                            Brian Bolan headshot

                                            Lessons Of A Biotech Blowup

                                            by Brian Bolan

                                            Biotechs are risky plays, even for the "smart money"